JohansenMD, HerrmannJ-L, KremerL. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol, 2020; 18(7):392–407; doi: 10.1038/s41579-020-0331-1
2.
DerbyshireKM, SalfingerM. Plasmid-mediated drug resistance in mycobacteria: The tip of the iceberg? J Clin Microbiol, 2023; 61(10):e00628-23; doi: 10.1128/jcm.00628-23
3.
SteinEA, BaysH, O’BrienD, et al.Lapaquistat acetate: Development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation, 2011; 123(18):1974–1985; doi: 10.1161/CIRCULATIONAHA.110.97528
MyasoedovaVA, RavaniAL, FrigerioB, et al.Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments. Pharmacol Res, 2018; 136:74–82; doi: 10.1016/j.phrs.2018.08.020
6.
SpurgeonS, YuM, PhillipsJD, et al.Cladribine: Not just another purine analogue? Expert Opin Investig Drugs, 2009; 18(8):1169–1181; doi: 10.1517/13543780903071038
7.
Tavares-CarreonF, Anda-MoraKD, Rojas-BarreraIC, et al.Serratia marcescens antibiotic resistance mechanisms of an opportunistic pathogen: A literature review. PeerJ, 2023; 11:e14399; doi: 10.7717/peerj.14399
8.
KimGM, ParkH, LeeSY. Roles of osteoclast-associated receptor in rheumatoid arthritis and osteoarthritis. Joint Bone Spine, 2022; 89(5):105400; doi: 10.1016/j.jbspin.2022.105400
9.
HaywoodJ, QiJ, ChenC-C, et al.Structural basis of collagen recognition by human osteoclast-associated receptor and design of osteoclastogenesis inhibitors. Proc Natl Acad Sci U S A, 2016; 113(4):1038–1043; doi: 10.1073/pnas.1522572113
10.
KwonY, ParkS, LeeJ, et al.BEAR: A novel virtual screening method based on large-scale bioactivity data. J Chem Inf Model, 2023; 63(5):1429–1437; doi: 10.1021/acs.jcim.2c01300
11.
KimDH, SungDH, MinYK. Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: Focus on manifestations in the skeletal system and literature review. J Bone Miner Metab, 2013; 31(2):240–246; doi: 10.1007/s00774-012-0384-y
12.
FabbriM, FerreiraJJ, RascolO. COMT inhibitors in the management of Parkinson’s Disease. CNS Drugs, 2022; 36(3):261–282; doi: 10.1007/s40263-021-00888-9
13.
HartungJE, CiszekBP, NackleyAG. β2- and β3-adrenergic receptors drive COMT-dependent pain by increasing production of nitric oxide and cytokines. Pain, 2014; 155(7):1346–1355; doi: 10.1016/j.pain.2014.04.011
14.
PetersonYK, CameronRB, WillsLP, et al.β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis. Bioorg Med Chem Lett, 2013; 23(19):5376–5381; doi: 10.1016/j.bmcl.2013.07.052
15.
ArifE, SolankiAK, SrivastavaP, et al.Mitochondrial biogenesis induced by the β2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury. Kidney Int, 2019; 96(3):656–673; doi: 10.1016/j.kint.2019.03.023
16.
BrownJE, AdamsonJW. Modulation of in vitro erythropoiesis. The influence of beta-adrenergic agonists on erythroid colony formation. J Clin Invest, 1977; 60(1):70–77; doi: 10.1172/JCI108771
17.
KallioraC, DrosatosK. The glitazars paradox: Cardiotoxicity of the metabolically beneficial dual PPARα and PPARγ activation. J Cardiovasc Pharmacol, 2020; 76(5):514–526; doi: 10.1097/FJC.0000000000000891
18.
GunduzOH, Kenis-CoskunO. Ganglion blocks as a treatment of pain: Current perspectives. J Pain Res, 2017; 10:2815–2826; doi: 10.2147/JPR.S134775
19.
FeiginG, Velasco FigueroaS, EnglesakisMF, et al.Stellate ganglion block for non-pain indications: A scoping review. Pain Med, 2023; 24(7):775–781; doi: 10.1093/pm/pnad011
20.
KerznerJ, LiuH, DemchenkoI, et al.Stellate ganglion block for psychiatric disorders: A systematic review of the clinical research landscape. Chronic Stress (Thousand Oaks), 2021; 5:24705470211055176; doi: 10.1177/24705470211055176
21.
KatsikiN, NikolicD, MontaltoG, et al.The role of fibrate treatment in dyslipidemia: An overview. Curr Pharm Des, 2013; 19(17):3124–3131; doi: 10.2174/1381612811319170020
22.
ChoiJ-M, BothwellALM. The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells, 2012; 33(3):217–222; doi: 10.1007/s10059-012-2297-y
23.
ChekaouiA, ErtlHCJ. PPARα agonist fenofibrate enhances cancer vaccine efficacy. Cancer Res, 2021; 81(17):4431–4440; doi: 10.1158/0008-5472.CAN-21-0052
24.
DeeksED. Flibanserin: First global approval. Drugs, 2015; 75(15):1815–1822; doi: 10.1007/s40265-015-0474-y
25.
van RoyenME, van CappellenWA, de VosC, et al.Stepwise androgen receptor dimerization. J Cell Sci, 2012; 125(Pt 8):1970–1979; doi: 10.1242/jcs.096792
26.
MasiulisS, DesaiR, UchańskiT, et al.GABAA receptor signalling mechanisms revealed by structural pharmacology. Nature, 2019; 565(7740):454–459; doi: 10.1038/s41586-018-0832-5
27.
ShinDJ, GermannAL, JohnsonAD, et al.Propofol is an allosteric agonist with multiple binding sites on concatemeric ternary GABAA receptors. Mol Pharmacol, 2018; 93(2):178–189; doi: 10.1124/mol.117.110403
28.
UzunS, KozumplikO, JakovljevićM, et al.Side effects of treatment with benzodiazepines. Psychiatr Danub, 2010; 22(1):90–93.
29.
YuL, ZhuX, PengK, et al.Propofol alleviates anxiety-like behaviors associated with pain by inhibiting the hyperactivity of PVNCRH neurons via GABAA receptor β3 subunits. Adv Sci (Weinh), 2024; 11(28):e2309059; doi: 10.1002/advs.202309059
30.
Pushparajah MakRS, LiebeltEL. Methylene blue: An antidote for Methemoglobinemia and beyond. Pediatr Emerg Care, 2021; 37(9):474–477; doi: 10.1097/PEC.0000000000002526
31.
FloydRA, WestMS, EneffKL, et al.Methylene blue plus light mediates 8-hydroxyguanine formation in DNA. Arch Biochem Biophys, 1989; 273(1):106–111; doi: 10.1016/0003-9861(89)90167-7
32.
LemppFA, SchlundF, RiebleL, et al.Recapitulation of HDV infection in a fully permissive hepatoma cell line allows efficient drug evaluation. Nat Commun, 2019; 10(1):2265; doi: 10.1038/s41467-019-10211-2
33.
SomatilakaBN, SadekA, McKayRM, et al.Malignant peripheral nerve sheath tumor: Models, biology, and translation. Oncogene, 2022; 41(17):2405–2421; doi: 10.1038/s41388-022-02290-1
34.
RhodesSD, HeY, SmithA, et al.Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Hum Mol Genet, 2019; 28(16):2752–2762; doi: 10.1093/hmg/ddz095
35.
CiacciarelliM, ZerbinatiC, VioliF, et al.Dipyridamole: A drug with unrecognized antioxidant activity. Curr Top Med Chem, 2015; 15(9):822–829; doi: 10.2174/1568026615666150220111942
36.
BalakumarP, NyoYH, RenushiaR, et al.Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? Pharmacol Res, 2014; 87:144–150; doi: 10.1016/j.phrs.2014.05.008
MeerupallyR, SinghJN, SharmaSS. Diabetic-induced increased sodium channel activity attenuated by tetracaine in sensory neurons in vitro. Biochem Biophys Res Commun, 2014; 453(3):296–301; doi: 10.1016/j.bbrc.2014.09.035
39.
YanagiK, HaradaS. Destabilization of herpes simplex virus type 1 virions by local anesthetics, alkaline pH, and calcium depletion. Arch Virol, 1989; 108(1–2):151–159; doi: 10.1007/BF01313753
40.
KaminesterLH, PariserRJ, PariserDM, et al.A double-blind, placebo-controlled study of topical tetracaine in the treatment of herpes labialis. J Am Acad Dermatol, 1999; 41(6):996–1001; doi: 10.1016/S0190-9622(99)70260-4
